MRNA vs. REGN: Moderna vs. Regeneron Pharmaceuticals Stock Comparison
How do Moderna (MRNA) and Regeneron Pharmaceuticals (REGN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Moderna (MRNA) and Regeneron Pharmaceuticals (REGN) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | MRNA | REGN |
|---|---|---|
| Name | Moderna Inc. | Regeneron Pharmaceuticals, Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 101.48 billion USD | 93.55 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | December 7, 2018 | April 2, 1991 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MRNA | REGN |
|---|---|---|
| Total Return (1Y) | 1,031.66% | 40.87% |
| Total Return (3Y, Annualized) | 58.68% | 5.15% |
| Total Return (5Y, Annualized) | 3.23% | 8.58% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas Regeneron Pharmaceuticals (REGN) sees a more moderate 772.95K — larger orders in the latter may require more patience and tighter control over order sizing.
| Metric | MRNA | REGN |
|---|---|---|
| Volatility (1Y, Annualized) | 194.88% | 34.08% |
| Beta (5Y) | 1.08 | 0.10 |
| Max Drawdown (5Y) | -93.93% | -59.69% |
| Avg. Volume (3M) | 21.61M | 772.95K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MRNA | REGN |
|---|---|---|
| Sharpe Ratio (1Y) | 5.27 | 1.07 |
| Sortino Ratio (1Y) | 20.44 | 1.70 |
Profitability
ROE (TTM)
Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Regeneron Pharmaceuticals (REGN) reports 14.95%, ranking against industry peers normally.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.95%
- Max
- 109.18%
- REGN
- 14.95%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Regeneron Pharmaceuticals (REGN) reports 28.51%, ranking against industry peers normally.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.51%
- REGN
- 28.51%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Regeneron Pharmaceuticals (REGN) reports 40.46%, ranking against industry peers normally.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.46%
- Max
- 83.12%
- REGN
- 40.46%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MRNA | REGN |
|---|---|---|
| ROE (TTM) | -39.00% | 14.95% |
| ROA (TTM) | -13.26% | 7.59% |
| Net Margin (TTM) | -141.43% | 28.51% |
| Operating Margin (TTM) | -557.93% | 40.46% |
| Gross Margin (TTM) | -66.02% | 46.73% |
Growth
Revenue Growth
Regeneron Pharmaceuticals (REGN) at 0.99% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: Regeneron Pharmaceuticals (REGN) reports EPS growth of 8.19%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.
Growth Metrics
| Metric | MRNA | REGN |
|---|---|---|
| Revenue Growth (YoY) | -39.92% | 0.99% |
| Revenue Growth (3Y CAGR) | -53.30% | 5.62% |
| EPS Growth (YoY) | -- | 8.19% |
| EPS Growth (3Y CAGR) | -- | 2.77% |
Financial Strength
Current Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 3.35 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- REGN
- 3.35
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Moderna (MRNA) at 0.19 and Regeneron Pharmaceuticals (REGN) at 0.08 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.08
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- REGN
- 0.08
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MRNA | REGN |
|---|---|---|
| Current Ratio (MRQ) | 2.30 | 3.35 |
| Debt / Equity (MRQ) | 0.19 | 0.08 |
| Net Debt / EBITDA | -- | -1.17 |
Dividends
Dividend Yield (TTM)
Moderna (MRNA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a yield of 0.41%, ranking against industry peers normally.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.41%
- REGN
- 0.41%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Moderna (MRNA) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Regeneron Pharmaceuticals (REGN) reports a payout of 8.18%, ranking against industry peers normally.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.18%
- REGN
- 8.18%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MRNA | REGN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.41% |
| Dividend Payout Ratio (TTM) | 0.00% | 8.18% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Regeneron Pharmaceuticals (REGN) trades at 19.99 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.99
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- REGN
- 19.99
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Regeneron Pharmaceuticals (REGN) at 5.54 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.54
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- REGN
- 5.54
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Regeneron Pharmaceuticals (REGN) at 2.71 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
REGN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- REGN
- 2.71
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MRNA | REGN |
|---|---|---|
| P/E Ratio (TTM) | -- | 19.99 |
| P/S Ratio (TTM) | 45.55 | 5.54 |
| P/B Ratio (MRQ) | 11.58 | 2.71 |
| Free Cash Flow Yield (TTM) | 0.29% | 2.76% |